vs
Side-by-side financial comparison of AdvanSix Inc. (ASIX) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
AdvanSix Inc. is the larger business by last-quarter revenue ($359.9M vs $281.3M, roughly 1.3× Guardant Health, Inc.). AdvanSix Inc. runs the higher net margin — -0.8% vs -45.7%, a 44.9% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 9.4%). AdvanSix Inc. produced more free cash flow last quarter ($36.1M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 3.4%).
AdvanSix Inc. is an American chemical company that produces nylon 6 and related chemicals such as caprolactam and ammonium sulfate fertilizers. It operated as Honeywell's Resins and Chemicals division until 2016, when it was spun off as a separate company. The unit accounted for 3 percent of Honeywell's sales at the time. For 2019, revenue is estimated at $1.4 billion. The company traces its lineage to the H. W. Jayne Company, established 1884 in Frankford, Pennsylvania.
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
ASIX vs GH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $359.9M | $281.3M |
| Net Profit | $-2.8M | $-128.5M |
| Gross Margin | 7.6% | 64.6% |
| Operating Margin | -0.7% | -43.0% |
| Net Margin | -0.8% | -45.7% |
| Revenue YoY | 9.4% | 39.4% |
| Net Profit YoY | -892.9% | -15.8% |
| EPS (diluted) | $-0.11 | $-1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $359.9M | $281.3M | ||
| Q3 25 | $374.5M | $265.2M | ||
| Q2 25 | $410.0M | $232.1M | ||
| Q1 25 | $377.8M | $203.5M | ||
| Q4 24 | $329.1M | $201.8M | ||
| Q3 24 | $398.2M | $191.5M | ||
| Q2 24 | $453.5M | $177.2M | ||
| Q1 24 | $336.8M | $168.5M |
| Q4 25 | $-2.8M | $-128.5M | ||
| Q3 25 | $-2.6M | $-92.7M | ||
| Q2 25 | $31.4M | $-99.9M | ||
| Q1 25 | $23.3M | $-95.2M | ||
| Q4 24 | $352.0K | $-111.0M | ||
| Q3 24 | $22.3M | $-107.8M | ||
| Q2 24 | $38.9M | $-102.6M | ||
| Q1 24 | $-17.4M | $-115.0M |
| Q4 25 | 7.6% | 64.6% | ||
| Q3 25 | 6.8% | 64.7% | ||
| Q2 25 | 14.3% | 65.0% | ||
| Q1 25 | 14.2% | 63.3% | ||
| Q4 24 | 3.4% | 61.6% | ||
| Q3 24 | 14.4% | 61.1% | ||
| Q2 24 | 17.9% | 59.1% | ||
| Q1 24 | 0.9% | 61.2% |
| Q4 25 | -0.7% | -43.0% | ||
| Q3 25 | -0.9% | -37.3% | ||
| Q2 25 | 7.7% | -45.9% | ||
| Q1 25 | 7.7% | -54.6% | ||
| Q4 24 | -3.9% | -62.4% | ||
| Q3 24 | 7.5% | -61.3% | ||
| Q2 24 | 11.5% | -56.8% | ||
| Q1 24 | -7.0% | -59.2% |
| Q4 25 | -0.8% | -45.7% | ||
| Q3 25 | -0.7% | -35.0% | ||
| Q2 25 | 7.7% | -43.0% | ||
| Q1 25 | 6.2% | -46.8% | ||
| Q4 24 | 0.1% | -55.0% | ||
| Q3 24 | 5.6% | -56.3% | ||
| Q2 24 | 8.6% | -57.9% | ||
| Q1 24 | -5.2% | -68.2% |
| Q4 25 | $-0.11 | $-1.01 | ||
| Q3 25 | $-0.10 | $-0.74 | ||
| Q2 25 | $1.15 | $-0.80 | ||
| Q1 25 | $0.86 | $-0.77 | ||
| Q4 24 | $0.02 | $-0.90 | ||
| Q3 24 | $0.82 | $-0.88 | ||
| Q2 24 | $1.43 | $-0.84 | ||
| Q1 24 | $-0.65 | $-0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $19.8M | $378.2M |
| Total DebtLower is stronger | — | $1.5B |
| Stockholders' EquityBook value | $815.2M | $-99.3M |
| Total Assets | $1.7B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.8M | $378.2M | ||
| Q3 25 | $23.7M | $580.0M | ||
| Q2 25 | $18.4M | $629.1M | ||
| Q1 25 | $8.3M | $698.6M | ||
| Q4 24 | $19.6M | $525.5M | ||
| Q3 24 | $17.3M | $585.0M | ||
| Q2 24 | $12.1M | $933.7M | ||
| Q1 24 | $20.6M | $1.0B |
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $815.2M | $-99.3M | ||
| Q3 25 | $818.2M | $-354.5M | ||
| Q2 25 | $823.7M | $-305.5M | ||
| Q1 25 | $794.4M | $-250.8M | ||
| Q4 24 | $774.6M | $-139.6M | ||
| Q3 24 | $766.4M | $-60.1M | ||
| Q2 24 | $746.6M | $-1.6M | ||
| Q1 24 | $713.2M | $68.3M |
| Q4 25 | $1.7B | $2.0B | ||
| Q3 25 | $1.7B | $1.3B | ||
| Q2 25 | $1.6B | $1.3B | ||
| Q1 25 | $1.6B | $1.3B | ||
| Q4 24 | $1.6B | $1.5B | ||
| Q3 24 | $1.5B | $1.5B | ||
| Q2 24 | $1.5B | $1.6B | ||
| Q1 24 | $1.5B | $1.7B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $63.7M | $-26.4M |
| Free Cash FlowOCF − Capex | $36.1M | $-54.2M |
| FCF MarginFCF / Revenue | 10.0% | -19.3% |
| Capex IntensityCapex / Revenue | 7.7% | 9.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $6.4M | $-233.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.7M | $-26.4M | ||
| Q3 25 | $26.6M | $-35.4M | ||
| Q2 25 | $21.1M | $-60.3M | ||
| Q1 25 | $11.4M | $-62.7M | ||
| Q4 24 | $64.2M | $-64.5M | ||
| Q3 24 | $57.3M | $-51.1M | ||
| Q2 24 | $50.2M | $-94.0M | ||
| Q1 24 | $-36.2M | $-30.3M |
| Q4 25 | $36.1M | $-54.2M | ||
| Q3 25 | $66.0K | $-45.8M | ||
| Q2 25 | $-7.2M | $-65.9M | ||
| Q1 25 | $-22.6M | $-67.1M | ||
| Q4 24 | $29.8M | $-83.4M | ||
| Q3 24 | $26.8M | $-55.3M | ||
| Q2 24 | $16.7M | $-99.1M | ||
| Q1 24 | $-71.6M | $-37.2M |
| Q4 25 | 10.0% | -19.3% | ||
| Q3 25 | 0.0% | -17.3% | ||
| Q2 25 | -1.7% | -28.4% | ||
| Q1 25 | -6.0% | -33.0% | ||
| Q4 24 | 9.1% | -41.3% | ||
| Q3 24 | 6.7% | -28.9% | ||
| Q2 24 | 3.7% | -55.9% | ||
| Q1 24 | -21.3% | -22.1% |
| Q4 25 | 7.7% | 9.9% | ||
| Q3 25 | 7.1% | 3.9% | ||
| Q2 25 | 6.9% | 2.4% | ||
| Q1 25 | 9.0% | 2.2% | ||
| Q4 24 | 10.4% | 9.4% | ||
| Q3 24 | 7.7% | 2.2% | ||
| Q2 24 | 7.4% | 2.9% | ||
| Q1 24 | 10.5% | 4.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 182.29× | — | ||
| Q3 24 | 2.57× | — | ||
| Q2 24 | 1.29× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
